|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0021760,
umls-concept:C0246415,
umls-concept:C0376358,
umls-concept:C0441655,
umls-concept:C0521447,
umls-concept:C0681842,
umls-concept:C0683598,
umls-concept:C1136689,
umls-concept:C1521840,
umls-concept:C2349975
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2006-9-26
|
|
pubmed:abstractText |
To investigate whether nuclear factor kappaB (NF-kappaB)/interleukin 6 (IL-6) was linked to docetaxel response in human prostate cancer cell lines, and whether inhibition of NF-kappaB sensitized tumor cells to docetaxel. We also aimed to correlate IL-6 (as a surrogate marker of NF-kappaB) and docetaxel response in hormone-independent prostate cancer (HIPC) patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AlbanellJoanJ,
pubmed-author:BoschMartaM,
pubmed-author:CampásClaraC,
pubmed-author:Codony-ServatJordiJ,
pubmed-author:DangLennyL,
pubmed-author:Domingo-DomenechJosepJ,
pubmed-author:FilellaXavierX,
pubmed-author:GasconPereP,
pubmed-author:MelladoBegoñaB,
pubmed-author:MontagutClaraC,
pubmed-author:OlivaCristinaC,
pubmed-author:RolfeMarkM,
pubmed-author:RossJeffrey SJS,
pubmed-author:RoviraAnaA,
pubmed-author:TapiaMarianM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5578-86
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17000695-Aged,
pubmed-meshheading:17000695-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17000695-Bone Neoplasms,
pubmed-meshheading:17000695-Cell Survival,
pubmed-meshheading:17000695-Disease Progression,
pubmed-meshheading:17000695-Dose-Response Relationship, Drug,
pubmed-meshheading:17000695-Drug Evaluation, Preclinical,
pubmed-meshheading:17000695-Drug Resistance, Neoplasm,
pubmed-meshheading:17000695-Drug Synergism,
pubmed-meshheading:17000695-Heterocyclic Compounds, 3-Ring,
pubmed-meshheading:17000695-Humans,
pubmed-meshheading:17000695-Interleukin-6,
pubmed-meshheading:17000695-Lymph Nodes,
pubmed-meshheading:17000695-Male,
pubmed-meshheading:17000695-Middle Aged,
pubmed-meshheading:17000695-NF-kappa B,
pubmed-meshheading:17000695-Neoplasm Metastasis,
pubmed-meshheading:17000695-Prognosis,
pubmed-meshheading:17000695-Prostate-Specific Antigen,
pubmed-meshheading:17000695-Prostatic Neoplasms,
pubmed-meshheading:17000695-Pyridines,
pubmed-meshheading:17000695-Statistics as Topic,
pubmed-meshheading:17000695-Survival Analysis,
pubmed-meshheading:17000695-Taxoids,
pubmed-meshheading:17000695-Tumor Cells, Cultured
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
|
|
pubmed:affiliation |
Department of Medical Oncology and Laboratory of Experimental Oncology, Institut Clinic Malalties Hemato-Oncologiques, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
